News
-
Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration With AstraZeneca
9/10/2012
Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner, AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity. AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity.
-
ImaginAb And MacroGenics Collaborate To Develop In Vivo Imaging Agents For Autoimmune Diseases, Cancer
9/5/2012
ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, recently announced that it has entered into a collaboration and commercialization agreement with MacroGenics, Inc.
-
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
8/23/2012
Janssen Biologics (Ireland) announced today it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK).
-
As Tuberculosis Grows More Difficult To Control, Vaccine Candidate To Prevent Disease Enters Clinical Testing
8/22/2012
Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE. The Phase I clinical trial will assess the safety, tolerability and immunogenicity of the vaccine candidate in 60 healthy adult volunteers. The study will be conducted by Johnson County Clin-Trials in Lenexa, Kansas, in close collaboration with Aeras and IDRI.
-
Merck Signs Two Deals For Novel HIV Drug Candidates And Initiates Phase II Clinical Trial Of MK-1439 For HIV
7/24/2012
Merck, known as MSD outside the United States and Canada, announced recently that the company has signed two licensing agreements for investigational HIV drug candidates.
-
Dalton Pharma Services Supports Client Milestone In Dengue Treatment Clinical Trial
7/24/2012
A clinical trial to treat dengue fever with a new antiviral medicine, Celgosivir, has been initiated in Singapore. The trial follows successful mouse model studies by researchers at the Duke-National University of Singapore (NUS) Graduate Medical School, who established its efficacy (1). Celgosivir, also known as butyl-castanospermine, is derived from the seeds of the Moreton Bay Chestnut tree.
-
HIV Immunity Study Could Pave Way For Vaccine Development
7/17/2012
Two Los Alamos National Laboratory scientists are among the team recently funded to explore ways to create the precise immune factors needed for effective vaccines against HIV.
- Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% Of Flu Deaths 7/10/2012
-
Next Front In Worldwide AIDS Battle: Stretching Use Of Anti-HIV Drugs
7/5/2012
A Johns Hopkins expert in the drug treatment of HIV disease and AIDS is spearheading an international effort to radically shift the manufacturing and prescribing of combination therapies widely credited in the last decade for keeping the disease in check for 8 million of the 34 million infected people worldwide.
-
Sinovac Reports Progress In EV71 Vaccine Phase III Clinical Trial And Commercialization Preparation Status
6/25/2012
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today provided an update on its Phase III clinical trial progress and commercialization preparation for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD).